ADVANCES IN THE DIAGNOSIS PATHOGENESIS AND TREATMENT OF CIDP PDF

Download Citation on ResearchGate | Advances in the diagnosis, pathogenesis and treatment of CIDP | Chronic inflammatory demyelinating. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens. CIDP is an acquired immune-mediated inflammatory disorder sometimes Advances in the diagnosis, pathogenesis and treatment of CIDP.

Author: Vudodal Voktilar
Country: Tanzania
Language: English (Spanish)
Genre: Travel
Published (Last): 13 February 2009
Pages: 482
PDF File Size: 19.80 Mb
ePub File Size: 16.98 Mb
ISBN: 963-1-31377-342-4
Downloads: 99350
Price: Free* [*Free Regsitration Required]
Uploader: Duzil

Advances in the diagnosis, pathogenesis and treatment of CIDP

New biomarkers and scoring systems represent emerging tools with the potential to predict therapeutic responses and identify patients with active disease for enrollment into clinical trials. Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy Marinos C. Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies.

John David PollardPatricia J. Bertsias Current opinion in rheumatology From This Paper Figures, tables, and topics from this paper. Citations Publications citing this paper.

Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: BoumpasGeorge K. Armati Journal of the peripheral nervous system: Showing of 60 extracted citations. Advances in our understanding of the underlying immunopathology in CIDP have identified new targets for future therapeutic efforts, including T cells, B cells, and transmigration and transduction molecules.

  ANALISIS INTRODUCTORIO DE CIRCUITOS ELECTRICOS ROBERT L BOYLESTAD PDF

Despite clinical challenges in diagnosis—owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination—consensus criteria seem to have been reached for research or clinical practice. Commonly used immunosuppressive drugs offer minimal benefit, necessitating the development of new therapies for treatment-refractory patients.

Advances in the diagnosis, pathogenesis and treatment of CIDP.

References Publications referenced by this paper. Showing of references.

Antonis FanouriakisDimitrios T. By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy PolicyTerms of Serviceand Dataset Pathigenesis. Skip to search form Skip to main content. Dalakas The Lancet Pathogenesiss Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Immunoglobulins, Intravenous Demyelinating peripheral neuropathy Polyneuropathy.

Brannagan Journal of the peripheral nervous system: This paper has been referenced on Twitter 1 time over the past 90 days. This Review highlights the recent advances in diagnosing CIDP, provides an update on the immunopathology including new target antigens, and discusses current treatments, ongoing challenges and future therapeutic directions.

Evidence from Human and Animal Studies: Maintenance therapy with IVIg can induce sustained remission, increase quality of life and prevent further axonal loss, but caution is needed to avoid overtreatment. Pathogenesis and treatment of CNS lupus.

  ESTRUCTURA DE DATOS Y ORGANIZACION DE ARCHIVOS LOOMIS PDF

Advances in the diagnosis, pathogenesis and treatment of CIDP.

An update on the management of chronic inflammatory demyelinating polyneuropathy. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating teatment.

Kenneth Craig Gorson Therapeutic advances in neurological disorders Despite clinical challenges in diagnosis-owing in part to the existence of disease variants, and different views on how many electrophysiological abnormalities are needed to document demyelination-consensus criteria seem to have been reached for research or clinical practice.

Thf inflammatory demyelinating polyneuropathy CIDP is the most common chronic autoimmune neuropathy. Current diagnosis of CIDP: An open label clinical trial of complement inhibition in multifocal motor neuropathy. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Search for additional papers on this topic.

MRI assessment including apparent diffusion coefficient. Topics Discussed in This Paper.